Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial

Am Heart J. 2014 Jul;168(1):23-9.e2. doi: 10.1016/j.ahj.2014.03.021. Epub 2014 Apr 5.

Abstract

Patients with cardiovascular disease and impaired glucose tolerance are at increased risk of cardiovascular events and type 2 diabetes mellitus (T2DM). Lifestyle modification or pharmacological intervention can delay progression to T2DM, but there is no clear evidence that they reduce cardiovascular risk in this population. Acarbose, an α-glucosidase inhibitor that lowers postprandial blood glucose, has been shown to reduce T2DM risk by 25%, and possibly cardiovascular risk in impaired glucose tolerance subjects without cardiovascular disease.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acarbose / therapeutic use*
  • Blood Glucose / drug effects
  • Blood Glucose / metabolism*
  • Coronary Disease / blood
  • Coronary Disease / complications
  • Coronary Disease / prevention & control*
  • Diabetes Mellitus, Type 2 / blood
  • Diabetes Mellitus, Type 2 / complications
  • Diabetes Mellitus, Type 2 / prevention & control*
  • Disease Progression
  • Double-Blind Method
  • Follow-Up Studies
  • Glucose Intolerance / blood
  • Glucose Intolerance / complications
  • Glucose Intolerance / drug therapy*
  • Humans
  • Hypoglycemic Agents / therapeutic use
  • Prospective Studies
  • Secondary Prevention / methods*
  • Treatment Outcome

Substances

  • Blood Glucose
  • Hypoglycemic Agents
  • Acarbose